Luye Pharma Group Ltd.
Symbol: 2186.HK
HKSE
3.02
HKDDzisiejsza cena rynkowa
19.0836
Wskaźnik P/E
1.7261
Wskaźnik PEG
11.36B
Kapitalizacja MRK
- 0.00%
Rentowność DIV
Luye Pharma Group Ltd. (2186-HK) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 30442.4 | 8522.3 | 5544.3 | 5510.3 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 8899.94 | 2867.5 | 3220.5 | 3072.1 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 9083.1 | 2354.9 | 1783.7 | 1765.1 | ||||||||||||||||||||
balance-sheet.row.inventory | 3262.94 | 827.9 | 772.9 | 746.3 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 14658.34 | 3009.9 | 4658.7 | 5059.1 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 47624.65 | 10703.3 | 10785.8 | 10396.7 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 19926.44 | 5127.2 | 4909.1 | 4594.5 | ||||||||||||||||||||
balance-sheet.row.goodwill | 4170.88 | 1041.9 | 1003.4 | 985.4 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 25053.85 | 6317.9 | 5984.7 | 5441.8 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 29224.74 | 7359.8 | 6988.1 | 6427.2 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 1699.95 | 1968.4 | -2106.4 | -2489.9 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 291.01 | 144.6 | 113.9 | 133.1 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 4815.04 | 187.4 | 3559.1 | 3520.4 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 55957.17 | 14787.4 | 13463.8 | 12185.4 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 103581.81 | 25490.7 | 24249.6 | 22582.1 | ||||||||||||||||||||
balance-sheet.row.account-payables | 2864.67 | 767.2 | 559.9 | 570.9 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 25899.19 | 5195.8 | 6839.8 | 5263.2 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 565.73 | 294.9 | 256.3 | 205.1 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 10671.39 | 3228.2 | 2264.7 | 4227.6 | ||||||||||||||||||||
Deferred Revenue Non Current | 264.72 | 103.6 | 175 | 209.4 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 94.99 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 10345.67 | 2193.4 | 2087.5 | 1496.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 13045.19 | 3824.4 | 3720.7 | 6138 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 223.17 | 70.6 | 38.5 | 42 | ||||||||||||||||||||
balance-sheet.row.total-liab | 52136.22 | 11962.2 | 13207.9 | 13468.2 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 1944.43 | 486.1 | 457 | 455.8 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 14005.23 | 0 | 6667.3 | 6061.8 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 16081.52 | 7885.8 | 254.5 | 534 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 15700.8 | 4159.3 | 2797.3 | 1436.4 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 47731.99 | 12531.2 | 10176 | 8488.1 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 103581.81 | 25490.7 | 24249.6 | 22582.1 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 3713.61 | 997.3 | 865.8 | 625.8 | ||||||||||||||||||||
balance-sheet.row.total-equity | 51445.6 | 13528.5 | 11041.7 | 9113.9 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 103581.81 | - | - | - | ||||||||||||||||||||
Total Investments | 7732.43 | 1968.4 | 1114.1 | 582.2 | ||||||||||||||||||||
balance-sheet.row.total-debt | 36570.58 | 8423.9 | 9104.5 | 9490.8 | ||||||||||||||||||||
balance-sheet.row.net-debt | 18731.27 | 2769.1 | 6780.8 | 7052.5 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 532.61 | 669.8 | -74.6 | 942.2 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 331.43 | 671.3 | 582 | 510.9 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | -914.59 | 0 | -311.9 | -505.9 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 20.64 | 25.4 | 50 | 50.9 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 186.15 | 319.8 | -418.1 | -300.3 | |||||||||||||||||||
cash-flows.row.account-receivables | -403.05 | -18.8 | -211.8 | 145 | |||||||||||||||||||
cash-flows.row.inventory | -30.67 | -26.6 | -134 | 4.9 | |||||||||||||||||||
cash-flows.row.account-payables | 118.98 | 18.8 | 211.8 | -145 | |||||||||||||||||||
cash-flows.row.other-working-capital | 619.86 | 346.4 | -284 | -305.2 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | -381.1 | -32.5 | 355 | 335.7 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 689.73 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -544.22 | -1163.7 | -1541.6 | -1519.9 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 0.11 | 0 | -808.5 | -450.8 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -218.72 | -3485.9 | -3975.7 | -2859.2 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 627.68 | 2899.5 | 1919 | 4153.8 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -78.02 | 91.8 | 970.7 | 814.2 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -78.02 | -1658.3 | -3436 | 138.2 | |||||||||||||||||||
cash-flows.row.debt-repayment | -561.84 | -8301.9 | -7536.7 | -5896.7 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 1043.83 | 189.2 | 1044.5 | 7326.7 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -78 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | -175.5 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 1522.95 | 8166.9 | 8371.1 | -922.6 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 1522.95 | 54.1 | 1878.9 | 254 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 14.37 | -164.1 | -52.4 | 112.4 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 3254.94 | -114.5 | -1427.1 | 1538 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 5899.82 | 2323.7 | 2438.3 | 3865.4 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 2644.89 | 2438.3 | 3865.4 | 2327.3 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 689.73 | 1653.8 | 182.4 | 1033.4 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -544.22 | -1163.7 | -1541.6 | -1519.9 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 145.51 | 490.1 | -1359.2 | -486.4 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 6143.08 | 6143.1 | 5981.7 | 5200.2 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 1938.9 | 1938.9 | 1841.1 | 1803.5 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 4204.18 | 4204.2 | 4140.5 | 3396.7 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 586.16 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 643.97 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 2056.17 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.3 | -73.3 | 155.2 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 3038.59 | 3175.4 | 3186.6 | 3113.9 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 4977.49 | 5114.4 | 5027.8 | 4917.4 | ||||||||||||||||||||
income-statement-row.row.interest-income | 465.49 | 117.1 | 88.7 | 102 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 347.02 | 675.5 | 471.8 | 399.5 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 2056.17 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -187.34 | -187.3 | -545.2 | -461.5 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.3 | -73.3 | 155.2 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | -187.34 | -187.3 | -545.2 | -461.5 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 347.02 | 675.5 | 471.8 | 399.5 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 634.89 | 701.9 | 671.3 | 582 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 1522.33 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 887.44 | 887.4 | 1215 | 387 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 700.1 | 700.1 | 669.8 | -74.6 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 161.02 | 161 | 86.5 | 70.2 | ||||||||||||||||||||
income-statement-row.row.net-income | 532.61 | 532.6 | 604.8 | -144.8 |
Często zadawane pytania
Ile wynosi Luye Pharma Group Ltd. (2186.HK) aktywów ogółem?
Luye Pharma Group Ltd. (2186.HK) całkowite aktywa to 25490715000.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 3238970000.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.684.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to 0.039.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to 0.087.
Jaki jest całkowity przychód firmy?
Całkowity przychód to 0.144.
Co to jest Luye Pharma Group Ltd. (2186.HK) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi 532605000.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 8423947000.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 3175450000.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 5654804000.000.